Compass Pathways Aandeel

Compass Pathways Investeringen

Totale Investeringen van Compass Pathways (CMPS) per 25 aug 2026.

Investeringen

0,00USD

Laatst bijgewerkt:

Totale Investeringen van Compass Pathways is 2026 0,00 USD. Totale Investeringen van Compass Pathways was 2025 469.000,00 USD. Het is daarmee % lager lager dan het jaar ervoor.

De Compass Pathways Investeringen historie

  • 3 jaar

  • 10 jaar

  • 25 jaar

  • Max

Investeringen
Date
Investeringen
1 jan 2018
0,00 USD
1 jan 2019
0,00 USD
1 jan 2020
529.000,00 USD
1 jan 2021
525.000,00 USD
1 jan 2022
469.000,00 USD
1 jan 2023
469.000,00 USD
1 jan 2024
469.000,00 USD
1 jan 2025
0,00 USD
De Compass Pathways Investeringen historie
JAARInvesteringenYoY
0,00USD-100,00%
469.000,00USD0,00%
469.000,00USD0,00%
469.000,00USD-10,67%
525.000,00USD-0,76%
529.000,00USD
0,00USD
0,00USD
Access this data via the Eulerpool API

Compass Pathways Aandelenanalyse

Wat doet Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Compass Pathways

Op Eulerpool vindt u de volledige historische ontwikkeling van Totale Investeringen Compass Pathways sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Totale beleggingen omvatten zowel kortlopende als langlopende effecten die door een bedrijf worden aangehouden.

USD van Totale Investeringen is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — Compass Pathways

Alle kengetallen — Compass Pathways